Normal view MARC view ISBD view

Checkpoint inhibitor therapy: Immune-related adverse event management/ Lori Davis, Mary Beth Casselbury, Sharon Wilson

By:

Davis Lori

Contributor(s):

Casselbury Mary Beth, Wilson Sharon

Material type: Text

TextDescription: Vol. 54 (11) pages 26-34 : Illustrations: 27 cmISSN:

0360-4039

Uniform titles:

Nursing 2024 November 2024

Subject(s):

Checkpoint inhibitor therapy, immune-related adverse events (irAEs), immune checkpoint inhibitors (ICIs), immunotherapy, oncology

List(s) this item appears in: Periodical index

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities.

There are no comments on this title.

to post a comment.

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat)
Other Databases (Google Scholar)
Online Stores (Bookfinder.com)
Open Library (openlibrary.org)